Voluntary ex ante transparency notice: Framework agreement on the purchase of the drug sehcat, Selenium (75-se) -tauroselcholic acid (denmark-copenhagen: Pharmaceutical products)
The purpose of the framework agreement is to secure the supply of the drug sehcat, Selenium (75-se) -tauroselcholic acid to the nuclear medicine departments of the regional hospitals.
The diagnosis of BAM can be obtained using (1) 14Cglycocholate breath and stool test, (2) determination of serum C4 (7[alpha]-hydroxy-4 cholesten-3-one) or FGF-19 levels, (3) 24-hour faecal BA output dosage, and (4) 75-selenium homocholic acid taurine (SeHCAT) test.
The SeHCAT test, performed at the Nuclear Medicine Department, is simple, fast, and well tolerated and requires two scans one week apart.
The SeHCAT test is currently available in twelve European countries and in Canada, but not in the USA; it is relatively expensive and it is usually available only at third-level centers.
The standard patient preparation requires the suspension of bile acid sequestrants and antidiarrheal drugs one week prior to the first appointment because of interference with test results and requires fasting at least 4 hr before taking the SeHCAT capsule (GE Healthcare).
The administered SeHCAT activity is very small (370 kBq), with an effective dose of radiation for an adult of 0.26 mSv and total absorbed radiation of 0.3Gy/kBq.
The first scan is usually performed 3 hr after SeHCAT capsule ingestion (370 kBq) while patients are still fasting.
This method is used by many authors and gives a reliable measure of SeHCAT retention.